Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Thomson Reuters
 More »

  • VC Investment: Not Quite Dead?
    The report, authored by PricewaterhouseCoopers/National Venture Capital Association MoneyTree(tm) and based on data from Thomson Reuters, said that investment in early-stage ...
    5-15-2013
  • Aastrom Starts Layoffs, Slashes Expenses as Phase III Trial Halted
    limb ischemia (CLI) drug candidate ixmyelocel-T. The company-which according to Thomson Reuters data has 71 employees-said it was halting enrollment in its Phase III REVIVE ...
    3-27-2013
  • Top 10 VC & Biopharma Equity Deals of 2012
    for all of 2012, as recorded by MoneyTree Report, produced by PwC and National Venture Capital Association based on data from Thomson Reuters, and released earlier this month. ...
    2-8-2013
  • Life Tech Results Overshadowed by Buyout Rumors
    consensus estimate of analysts by Thomson Reuters I/B/E/S. Non-GAAP Q4 net income inched up 1.4% to $195.9 million or $1.11 per share from $193.1 million or $1.05 per share. ...
    2-5-2013
  • Merck Dampens 2013 Expectations After Q4 Profits Slide
    Non-GAAP EPS excluding special items sunk 14.7% from 97 to 83 cents per share, just above the 81-cent EPS predicted by a consensus of analysts questioned by Thomson Reuters. Also ...
    2-1-2013
  • Personalized Cancer Treatment and Patient Stratification Using...
    clinical use. During this webinar sponsored by ESMO and Thomson Reuters, development of a novel and comprehensive set of knowledge resources and analytical tools will be presented. ...
    1-31-2013
  • Bittersweet News at Biogen Idec
    2011. Excluding special items, earnings per share were $1.40, down 7% from a year earlier and six cents or 4% below the consensus estimate of 25 analysts polled by Thomson Reuters. ...
    1-28-2013
  • More VC Deals, Fewer Dollars in Q4
    fourth quarter of 2011, according to the quarterly MoneyTree Report, issued by PricewaterhouseCoopers and the National Venture Capital Association based on Thomson Reuters data. ...
    1-18-2013
  • Mayans Give Big Data a Big Break
    the cost of the R&D pipelines but with no added corporate value, noted a Deloitte/Thomson Reuters report in 2011. However the most seismic changes are not about national or ...
    1-4-2013
  • The New Economics of Orphan Diseases
    Globally, Thomson Reuters reports orphan disease therapeutics grew at a compounded annual growth rate (CAGR) of nearly 26% between 2000 and 2010, versus a CAGR of 20% for nonorphan ...
    1-1-2013
  • Shionogi Takes 10% Stake in GSK-Pfizer Joint Venture
    Industry analysts have predicted the drug will be launched by late 2013, with sales ramping up to around $1 billion three years later, according to Thomson Reuters Pharma analyst ...
    10-29-2012
  • Reconstruction of Disease Pathology for Drug Discovery: Focus...
    In the Webinar, Respiratory Disease Experts and Thomson Reuters Will Discuss Different aspects of asthma and COPD biology and challenges in disease research Applicability of ...
    10-15-2012
  • It's Tool Time for VCs
    PwC joins with the National Venture Capital Association every quarter to release the MoneyTree Report on VC trends, based on Thomson Reuters data. Dollar Drought restates findings ...
    8-16-2012
  • Combined with Other Technologies, Combinatorial Chemistry Remains...
    ... In its 2011 "Year of Chemistry" report "The Changing Role of Chemistry in Drug Discovery," Thomson Reuters said, "Already the job description for many chemists has changed from the ...
    7-24-2012
  • VC Investors Shun Biotech Startups
    quarter of 2011, according to the quarterly MoneyTree Report, issued by PricewaterhouseCoopers LLP and the National Venture Capital Association based on Thomson Reuters data. ...
    7-20-2012

  • Journal Articles

  • Burden of Illness for an Employed Population with Chronic Obstructive...
    Kavita Nair, Vahram Ghushchyan, Jill Van Den Bos, Michael Halford, Gideon Tan, Feride Frech-Tamas, Joseph J. Doyle
    Population Health Management
    Objectives: Our objective was to quantify the direct and indirect costs of COPD in an employed population in the US. Methods: A retrospective analysis using Thomson Reuters ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll